India, July 17 -- Phio Pharmaceuticals Corp. (PHIO), a clinical-stage biotechnology company, announced the receipt of receiving multiple favorable patent actions in the United States, Canada, and Japan, further expanding protection for its proprietary INTASYL gene-silencing platform.
INTASYL is Phio's proprietary gene-silencing platform that uses modified small interfering RNA (siRNA) designed to target messenger RNA and block the production of proteins involved in cancer.
The company received three Notices of Allowance and one patent grant, strengthening its global intellectual property portfolio for INTASYL compounds across key international markets.
Phio said the expanded patent protection is expected to support research and developme...